Lititz Medicaid providers receive $831,119 for evaluation and management services in 2024

Dr. Mehmet Oz CMS Administrator
Dr. Mehmet Oz CMS Administrator
0Comments

Data from the U.S. Department of Health and Human Services Medicaid Provider Spending database shows Lititz Medicaid providers collected $831,119 for services grouped under the Evaluation and Management category in 2024. This amount is up 7.8% from 2023, when $771,094 in claims were filed for the same category.

Medicaid, a government health insurance initiative managed by states and jointly financed by federal and state funds, provides coverage to low-income individuals and families, seniors, children, and people with disabilities, making it a key part of the U.S. health care system.

Since Medicaid is funded by taxpayers, shifts in local billing reflect how public health care resources are allocated within a given community.

The Evaluation and Management category encompasses services defined by the care delivered, relying on standardized HCPCS and CPT code groupings. For analysis, each billing code was included in a specific service group using established code prefixes and number ranges, supporting accurate comparisons over time while preventing overlap in the rankings.

Evaluation and Management topped all Medicaid payment categories in Lititz during 2024, despite growth seen across multiple service lines.

Statewide in Pennsylvania, Evaluation and Management place fourth for total Medicaid payments in 2024.

From the five years preceding 2024, Medicaid funding for Evaluation and Management in Lititz rose $705,754, marking a 563% surge. The upward trend included notable increases recorded during 2020 and 2021.

While these services are delivered throughout Lititz, most Medicaid payments occurred in a small number of ZIP codes. In 2024, ZIP code 17543 accounted for $831,118 in payments, making up 100% of Medicaid disbursements for Evaluation and Management in the area.

For this group, a few individual billing codes represented the bulk of Medicaid payments.

Looking at the local increase, Medicaid payments in Lititz for Evaluation and Management grew 7.8% between 2024 and 2023, matching the 7.8% change across all Medicaid claim types in the city for the same timeframe.

Centers for Medicare & Medicaid Services reporting indicates that combined federal and state Medicaid expenditures reached about $871.7 billion in fiscal 2023—roughly 18% of total U.S. health expenses—up from about $613.5 billion in 2019, before the COVID-19 crisis.

This increase reflects nearly 40% growth over several years, largely attributed to enrollment increases and rising service use during and after the pandemic.

Recent federal budgets under the Trump administration have featured proposals to scale back Medicaid funding and alter its structure. The “One Big Beautiful Bill Act,” enacted in 2025, is projected to reduce federal Medicaid support by more than $1 trillion over 10 years and implement policies—such as work requirements and higher cost-sharing—that may restrict access and lower funding for some groups. These adjustments are anticipated to transfer more Medicaid expenses to the states and limit federal spending growth while the program continues to support tens of millions of Americans.

Medicaid Payments Tied to Evaluation and Management in Lititz, Pennsylvania Over Five Years

Year Total Medicaid Payments % Change From Previous Year
2020 $125,364 874.2%
2021 $696,338 455.4%
2022 $740,034 6.3%
2023 $771,094 4.2%
2024 $831,118 7.8%
Top Categories by Medicaid Payments in Lititz, Pennsylvania, 2024

Rank Category Medicaid Payments Share of City Total
1 Evaluation and Management $831,118 43.5%
2 Medicine Services and Procedures $430,170 22.5%
3 Temporary National Codes (Non-Medicare) $271,579 14.2%
4 Alcohol and Drug Abuse Treatment $145,934 7.6%
5 Ambulance and Other Transport Services and Supplies $128,524 6.7%
6 Pathology and Laboratory Procedures $93,202 4.9%
7 Radiology Procedures $7,926 0.4%
8 Procedures / Professional Services $698 <0.1%
9 Temporary Codes $317 <0.1%
10 Surgery $3 <0.1%
11 Drugs Administered Other than Oral Method $0 <0.1%
Top 20 HCPCS Codes Within the Evaluation and Management Category in Lititz, Pennsylvania, 2024

HCPCS Code Description Medicaid Payments Claims
99213 Office o/p est low 20 min $267,495 245
99284 Emergency dept visit mod mdm $216,219 68
99214 Office o/p est mod 30 min $134,145 97
99283 Emergency dept visit low mdm $98,777 56
99392 Prev visit est age 1-4 $36,165 21
99391 Per pm reeval est pat infant $33,049 24
99285 Emergency dept visit hi mdm $16,542 10
99393 Prev visit est age 5-11 $10,247 7
99282 Emergency dept visit sf mdm $7,052 9
99490 Chrnc care mgmt staff 1st 20 $5,005 10
99212 Office o/p est sf 10 min $4,703 6
99394 Prev visit est age 12-17 $1,030 1
99395 Prev visit est age 18-39 $301 1
99177 Ocular instrumnt screen bil $261 3
99173 Visual acuity screen $119 5

Note: HCPCS codes are listed for context within the group. Category totals and the rankings in this report are determined by standardized service groupings, not individual billing codes.

Details in this article are drawn from the U.S. Department of Health and Human Services Medicaid Provider Spending database. Access the source data here.



Related

Sean R. Keveney J.D., Chief Counsel of FDA

FDA cites Daud’s Specialties, LLC in Lancaster for 4 violations during March 18 inspection

Daud’s Specialties, LLC in Lancaster was inspected by the FDA on March 18 for food standards, labeling, economic factors and foodborne biological hazards, resulting in four violations.

Benjamin D. Moncarz Chief Financial Officer - FDA

Henry Schein, Inc. in Denver receives FDA inspection on April 2

On April 2, the FDA evaluated Henry Schein, Inc. in Denver, focusing on food composition, labeling, and foodborne biological hazards, based on information released on the FDA’s website.

Sridhar Mantha, Acting Chief Information Officer of FDA

FDA inspects Central Pennsylvania Blood Bank in Ephrata on March 11

The Central Pennsylvania Blood Bank in Ephrata was inspected by the FDA on March 11 regarding blood and blood product safety, based on information made available on the FDA’s website.